KEYNOTE-040 investigators. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study - Cohen, EE W; Soulières, D; Le Tourneau, C; Dinis, J; Licitra, L; Ahn, M J; Soria, A; Machiels, J P; Mach, N; Mehra, R; Burtness, B; Zhang, P; Cheng, J; Swaby, R F; Harrington, K J (Lancet, 2019)